Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/ratios-of-proteins-in-cerebrospinal-fluid-in-parkinson-s-disease-p7JFnvNzu0
References (33)
-
M. Delgado-Alvarado, B. Gago, I. Navalpotro‐Gómez, Haritz Jiménez-Urbieta, M. Rodriguez-Oroz (2016)
Biomarkers for dementia and mild cognitive impairment in Parkinson's diseaseMovement Disorders, 31
-
I. Mata, H. Checkoway, C. Hutter, A. Samii, John Roberts, Hojoong Kim, P. Agarwal, V. Álvarez, R. Ribacoba, P. Pástor, Oswaldo Lorenzo-Betancor, J. Infante, M. Sierra, P. Gómez-Garre, P. Mir, B. Ritz, S. Rhodes, A. Colcher, V. Deerlin, Kathryn Chung, J. Quinn, D. Yearout, Erica Martinez, F. Farin, J. Wan, K. Edwards, C. Zabetian (2012)
Common variation in the LRRK2 gene is a risk factor for Parkinson's diseaseMovement Disorders, 27
-
M. Emre, D. Aarsland, Richard Brown, D. Burn, C. Duyckaerts, Y. Mizuno, G. Broe, J. Cummings, D. Dickson, S. Gauthier, J. Goldman, C. Goetz, A. Korczyn, A. Lees, R. Levy, I. Litvan, I. McKeith, W. Olanow, W. Poewe, N. Quinn, C. Sampaio, E. Tolosa, B. Dubois (2007)
Clinical diagnostic criteria for dementia associated with Parkinson's diseaseMovement Disorders, 22
-
H. Vránová, E. Hényková, M. Kaiserová, K. Menšíková, M. Vaštík, J. Mareš, P. Hluštík, J. Zapletalová, M. Strnad, D. Stejskal, P. Kaňovský (2014)
Tau protein, beta-amyloid1–42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementiaJournal of the Neurological Sciences, 343
-
M. Delgado-Alvarado, B. Gago, A. Gorostidi, Haritz Jiménez-Urbieta, R. Dacosta-Aguayo, I. Navalpotro‐Gómez, J. Ruiz‐Martinez, A. Bergareche, J. Martí‐Massó, P. Martínez-Lage, A. Izagirre, M. Rodriguez-Oroz (2017)
Tau/α‐synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory studyMovement Disorders, 32
-
W. Maetzler, Inga Liepelt, M. Reimold, G. Reischl, C. Solbach, C. Becker, C. Schulte, T. Leyhe, S. Keller, A. Melms, T. Gasser, D. Berg (2009)
Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristicsNeurobiology of Disease, 34
-
D. Irwin, V. Lee, J. Trojanowski (2013)
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologiesNature Reviews Neuroscience, 14
-
I. Litvan, D. Aarsland, C. Adler, J. Goldman, J. Kulisevsky, B. Mollenhauer, M. Rodriguez-Oroz, A. Tröster, D. Weintraub (2011)
MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCIMovement Disorders, 26
-
D. Aarsland, B. Creese, M. Politis, K. Chaudhuri, D. Ffytche, D. Weintraub, C. Ballard (2017)
Cognitive decline in Parkinson diseaseNature Reviews Neurology, 13
-
C. Williams-Gray, J. Evans, A. Goris, T. Foltynie, M. Ban, T. Robbins, C. Brayne, B. Kolachana, D. Weinberger, S. Sawcer, R. Barker (2009)
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.Brain : a journal of neurology, 132 Pt 11
-
Y. Compta, L. Parkkinen, S. O'sullivan, J. Vandrovcova, J. Holton, C. Collins, T. Lashley, C. Kallis, David Williams, R. Silva, A. Lees, T. Révész (2011)
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?Brain : a journal of neurology, 134 Pt 5
-
J. Dalrymple-Alford, M. MacAskill, Chris Nakas, L. Livingston, C. Graham, G. Crucian, T. Melzer, J. Kirwan, R. Keenan, S. Wells, R. Porter, R. Watts, T. Anderson (2010)
The MoCANeurology, 75
-
J. Schicks, Matthis Synofzik, Claudia Schulte, Ludger Schöls (2010)
CSF Aβ42 and tau in Parkinson's disease with cognitive impairmentMovement Disorders, 25
-
A. Hughes, S. Daniel, L. Kilford, A. Lees, London Wcln, J. Hughes (1992)
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 55
-
Y. Compta, J. Pereira, J. Ríos, N. Ibarretxe‐Bilbao, C. Junqué, N. Bargalló, A. Cámara, M. Buongiorno, M. Fernández, Claustre Pont‐Sunyer, M. Marti (2013)
Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study.Parkinsonism & related disorders, 19 8
-
C. Gasca-Salas, A. Estanga, P. Clavero, I. Aguilar-Palacio, R. González-Redondo, J. Obeso, M. Rodriguez-Oroz (2014)
Longitudinal assessment of the pattern of cognitive decline in non-demented patients with advanced Parkinson's disease.Journal of Parkinson's disease, 4 4
-
C. Williams-Gray, S. Mason, J. Evans, T. Foltynie, C. Brayne, T. Robbins, R. Barker (2013)
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohortJournal of Neurology, Neurosurgery & Psychiatry, 84
-
C. Janvin, J. Larsen, D. Aarsland, K. Hugdahl (2006)
Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementiaMovement Disorders, 21
-
B. Mollenhauer, C. Trenkwalder, N. Ahsen, M. Bibl, P. Steinacker, P. Brechlin, J. Schindehuette, S. Poser, J. Wiltfang, M. Otto (2006)
Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease DementiaDementia and Geriatric Cognitive Disorders, 22
-
J. Toledo, P. Gopal, Kevin Raible, D. Irwin, J. Brettschneider, Samantha Sedor, Kayla Waits, S. Boluda, M. Grossman, V. Deerlin, Eddie Lee, S. Arnold, J. Duda, H. Hurtig, V. Lee, C. Adler, T. Beach, J. Trojanowski (2016)
Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathologyActa Neuropathologica, 131
-
Y. Compta, T. Valente, J. Saura, B. Segura, Á. Iranzo, M. Serradell, C. Junqué, E. Tolosa, F. Valldeoriola, E. Muñoz, J. Santamaria, A. Cámara, M. Fernández, J. Fortea, M. Buongiorno, J. Molinuevo, N. Bargalló, M. Marti (2015)
Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s diseaseJournal of Neurology, 262
-
I. Litvan, J. Goldman, A. Tröster, B. Schmand, D. Weintraub, R. Petersen, B. Mollenhauer, C. Adler, K. Marder, C. Williams-Gray, D. Aarsland, J. Kulisevsky, M. Rodriguez-Oroz, D. Burn, R. Barker, M. Emre (2012)
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelinesMovement Disorders, 27
-
Ju-Hee Kang (2016)
Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s DiseaseJournal of Movement Disorders, 9
-
Tessandra Stewart, Changqin Liu, C. Ginghinǎ, K. Cain, P. Auinger, B. Cholerton, Min Shi, Jing Zhang (2014)
Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.The American journal of pathology, 184 4
-
Changqin Liu, B. Cholerton, Min Shi, C. Ginghinǎ, K. Cain, P. Auinger, Jing Zhang (2015)
CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.Parkinsonism & related disorders, 21 3
-
O. Hansson, S. Hall, A. Öhrfelt, H. Zetterberg, K. Blennow, L. Minthon, K. Nägga, E. Londos, S. Varghese, N. Majbour, A. Al-Hayani, O. El-Agnaf (2014)
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s diseaseAlzheimer's Research & Therapy, 6
-
Y. Compta, M. Ezquerra, E. Muñoz, E. Tolosa, F. Valldeoriola, J. Ríos, A. Cámara, M. Fernández, M. Buongiorno, M. Marti (2011)
High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson diseaseNeuroscience Letters, 487
-
G. Halliday, J. Leverenz, J. Schneider, C. Adler (2014)
The neurobiological basis of cognitive impairment in Parkinson's diseaseMovement Disorders, 29
-
S. Hall, Y. Surova, A. Öhrfelt, K. Blennow, H. Zetterberg, O. Hansson (2016)
Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's DiseaseMovement Disorders, 31
-
M. Buongiorno, F. Antonelli, Y. Compta, Yolanda Fernández, J. Pavía, F. Lomeña, J. Ríos, I. Ramírez, J. García, M. Soler, A. Cámara, M. Fernández, Misericòrdia Basora, F. Salazar, G. Sánchez-Etayo, F. Valldeoriola, J. Barrio, M. Marti (2016)
Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.Journal of Alzheimer's disease : JAD, 55 3
-
G. Alves, Johannes Lange, K. Blennow, H. Zetterberg, U. Andreasson, M. Førland, O. Tysnes, J. Larsen, K. Pedersen (2014)
CSF Aβ42 predicts early-onset dementia in Parkinson diseaseNeurology, 82
-
K. Leaver, K. Poston (2015)
Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson’s disease patients? A Systematic ReviewNeuropsychology Review, 25
-
A. Siderowf, S. Xie, H. Hurtig, D. Weintraub, J. Duda, A. Chen-Plotkin, L. Shaw, V. Deerlin, J. Trojanowski, C. Clark (2010)
CSF amyloid β 1-42 predicts cognitive decline in Parkinson diseaseNeurology, 75
- Publisher
- Wiley
- Copyright
- © 2018 International Parkinson and Movement Disorder Society
- ISSN
- 0885-3185
- eISSN
- 1531-8257
- DOI
- 10.1002/mds.27518
- Publisher site
- See Article on Publisher Site
Abstract
Background: There is a need for biomarkers of dementia in PD.
Journal
Movement Disorders – Wiley
Published: Nov 1, 2018
Keywords: ; ; ; ;